AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy
Pays $200m Upfront
Executive Summary
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.
You may also be interested in...
Astex Bags Another Cancer Deal With MSD, This Time For ‘Undruggable’ p53 Target
The UK-based biotech will license its Pyramid platform to MSD to develop anticancer compounds targeting p53, a key transcription factor dubbed the ‘guardian of the genome’ that has proven highly complex and challenging to drug.
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Otilimab Failure Is A Blow For GSK’s Pipeline, With More Tests To Come
GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.